Matinas BioPharma Holdings, Inc. (MTNB) stock
MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)
Close on Nov 18, 2026Market cap $13.37MP/E –Yield –
Matinas BioPharma operating margin
Operating margin is operating income as a percentage of revenue.
Matinas BioPharma's operating margin for the twelve months ending Dec 31, 2023 was -2168.4%. For fiscal 2023 it was -2168.4%, against -771.3% the year before. The highest annual figure on record is -771.3% in fiscal 2022.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -2168.4% | −1397.1 |
| FY2022 | Dec 31, 2022 | -771.3% | +74183.2 |
| FY2021 | Dec 31, 2021 | -74954.5% | −59666.2 |
| FY2020 | Dec 31, 2020 | -15288.4% | +5779.0 |
| FY2019 | Dec 31, 2019 | -21067.4% | −8836.4 |
| FY2018 | Dec 31, 2018 | -12230.9% | −1206.3 |
| FY2017 | Dec 31, 2017 | -11024.6% | −5928.6 |
| FY2015 | Dec 31, 2015 | -5096.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2023 | Mar 31, 2023 | -509.7% | +18549.8 |
| Q4 FY2022 | Dec 31, 2022 | -515.5% | +9866.7 |
| Q3 FY2022 | Sep 30, 2022 | -513.8% | +5334.5 |
| Q2 FY2022 | Jun 30, 2022 | -557.4% | +4476.1 |
| Q1 FY2021 | Mar 31, 2021 | -19059.5% | −15268.4 |
| Q4 FY2020 | Dec 31, 2020 | -10382.2% | +3382.5 |
| Q3 FY2020 | Sep 30, 2020 | -5848.3% | +4463.4 |
| Q2 FY2019 | Jun 30, 2019 | -5033.5% | +2556.4 |
| Q2 FY2018 | Jun 30, 2018 | -3791.1% | +5063.6 |
| Q1 FY2018 | Mar 31, 2018 | -13764.7% | +16212.0 |
| Q4 FY2017 | Dec 31, 2017 | -10311.7% | – |
| Q3 FY2017 | Sep 30, 2017 | -7589.8% | – |
| Q2 FY2017 | Jun 30, 2017 | -8854.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -29976.8% | – |
See a number that looks wrong?